

QOPI® 2018 ROUND 2 MEASURE CHANGES

- New Measures = 0
- Revised Measures = 3
- Retired Measures = 2

Module	Measure	Measure Description	Description of change	Comments
CORE	25a	Documentation of patient's advance directives by the third office visit	Added Patient Reason (Declined) in the numerator as performance met	
CORE	25b	Height, weight, and BSA documented prior to chemotherapy*	Removed “curative” for measure to count toward all chemotherapy intent Add exclusion for patients receiving topical and intravesical chemotherapy	
CRC	71	Adjuvant chemotherapy recommended within 9 months of diagnosis for patients with AJCC Stage II or III rectal cancer	Current evidence does not support this measure	
NHL	80n	Percentage of patients with PET or PET-CT ordered by practice between 3 and 12 months after completion of treatment with curative intent for diffuse large B cell lymphoma (Lower Score – Better) (Top 5 Measure)	Added Treatment Type to Denominator Changed days to months in denominator	Timeframe did not change
NSCLC	85	Platinum doublet first-line chemotherapy or EGFR-TKI or other targeted therapy with documented DNA mutation received by patients with initial AJCC stage IV or distant metastatic NSCLC with performance status of 0-1 without prior history of chemotherapy	Removed from QOPI	To be re-written based on updated clinical practice